New Technology– category –
-
Novel Bispecific ADC ICP-B381, Targeting PSMA and STEAP1, Approved for Phase 1 Clinical Trials in China for Prostate Cancer; US IND Submission Underway
Prostate Warriors China Overview ICP-B381, a novel bispecific antibody-drug conjugate (ADC) designed to simultaneously target PSMA and STEAP1, has received approval from Chinese regulatory authorities to commence Phase 1 clinical trials ... -
Gan & Lee Pharmaceuticals Initiates Phase I Trial for Once-Weekly Oral GLP-1 Peptide GZC8072 in China, Targeting Obesity and Type 2 Diabetes
AllSci China Overview Gan & Lee Pharmaceuticals Co., Ltd. has commenced its Phase I clinical trial for GZC8072, a novel once-weekly oral GLP-1 receptor peptide agonist, targeting type 2 diabetes and weight management in overweight or...
